Kratom Sampling Plans: How One Scoop Becomes a COA

August 30, 2026

Last reviewed: August 30, 2026. Educational content for adults 21+. This is not medical or legal advice. Kiody does not sell concentrated 7-OH products.

Suggested page: Learning Center → Lab Testing & Product Quality
Secondary topics: representative kratom sample, kratom lot testing, composite sample, kratom COA sampling, reserve sample

The number on a kratom COA begins before the sample reaches the laboratory

A certificate of analysis can look impressively precise. It may report mitragynine to two decimal places, lead in parts per million, or a pathogen result as “not detected.” But the instrument only measures the material placed in front of it. If that material does not adequately represent the lot, a technically excellent analysis may produce a number that says little about the rest of the product.

This is why sampling belongs at the beginning of COA literacy—not at the end as a paperwork detail.

Imagine a pallet containing many bags of kratom powder. Material near the top of one bag may not represent material at the bottom of that bag. One bag may not represent every bag on the pallet. A sample taken after blending may not represent material before blending. Capsules collected from the first minutes of a run may not represent the end of the run. A liquid sampled before mixing may not match a liquid sampled after adequate mixing. And a microbial contaminant present in one small pocket may be missed by a scoop taken several feet away.

Those are different forms of sampling risk. They cannot be solved by asking the laboratory to run the same vial twice.

The U.S. Food and Drug Administration makes the principle unusually clear in its Bacteriological Analytical Manual: if samples are improperly collected, mishandled, or unrepresentative, the resulting laboratory findings may be meaningless. FDA also explains that a representative sample is especially important when pathogens or toxins are sparsely distributed. That warning applies naturally to kratom quality review even though FDA’s BAM chapter is a general food microbiology resource rather than a kratom-specific standard. FDA BAM Chapter 1

This guide explains what a sampling plan should answer, how the answers change by product and analyte, and what a careful reader can—and cannot—conclude from a COA.

Sampling, testing, and specification are three different things

These terms are often blended together in product marketing. They should remain separate.

Sampling is the process used to choose material from a defined lot. It answers questions such as where, when, how, and how much material was collected.

Testing is the laboratory process used to prepare and analyze that material. It includes the method, equipment, calibration, controls, analyst work, calculations, and reporting.

A specification is an acceptance criterion established before the result is reviewed. It answers whether the result is acceptable for a defined purpose.

A strong method cannot repair a weak sample. A representative sample does not compensate for an unsuitable analytical method. And a correct number does not create a pass or fail decision unless a relevant, pre-established specification is applied.

Legal compliance is another separate question. Some jurisdictions restrict botanical kratom, some regulate adult sales, some impose numerical 7-OH limits, and some distinguish natural leaf from concentrated, enhanced, synthesized, or semi-synthesized products. A laboratory result may be part of that review, but the COA alone does not interpret every applicable law.

What does “representative” mean?

A representative sample is selected and handled so the tested material provides a defensible picture of the defined lot for the specific characteristic being examined.

That definition contains several important limits:

The lot must be defined. A sample cannot represent an undefined universe of product.
The characteristic must be named. A plan suited to label review may be unsuitable for detecting a sparse pathogen.
Selection matters. Convenience sampling is not automatically representative sampling.
Handling matters. A good sample can be compromised after collection.
Representativeness is contextual. A plan may be reasonable for a uniform liquid assay but inadequate for heterogeneous dry powder or rare contamination.

The federal dietary-supplement current good manufacturing practice regulation provides a useful quality benchmark. Under 21 CFR §111.80, representative samples may be required from unique lots and shipments of components, in-process materials, finished batches, received products, and packaged and labeled products. For finished dietary-supplement batches, the rule refers to a sound statistical sampling plan or testing every finished batch. 21 CFR §111.80

That regulation should not be misread as an FDA endorsement of kratom’s federal marketing status. FDA currently states that kratom is not lawfully marketed as a dietary supplement, conventional-food additive, or approved drug. Part 111 is discussed here as an authoritative framework for understanding representative samples and quality systems—not as proof that any kratom product has lawful federal dietary-supplement status. FDA and Kratom

Start with the lot, not the scoop

“Lot tested” is not meaningful unless the lot is identifiable.

A useful lot definition should establish what material shares a common manufacturing or handling history. Depending on the operation, relevant boundaries may include:

the supplier’s source lot;
a shipment and the individual source lots within it;
a blending event;
a manufacturing batch;
a milling run;
a packaging run;
a capsule-filling run;
a liquid-mixing tank;
a date or shift boundary;
a reworked or reprocessed quantity; and
finished packages carrying one lot or control number.

Combining material does not automatically erase its history. If three supplier lots are blended into one finished batch, the record should preserve the relationship between all three source lots and the new batch. If a supplier changes the source lot halfway through a shipment, calling the entire shipment “one lot” may hide a meaningful source boundary. If finished packages from separate production events receive the same lot number, a later investigation may be unable to isolate the affected material.

The core traceability question is simple: if a complaint or unexpected test result appears six months later, can the business identify which raw material, equipment, production records, packages, customers, and reserve samples are connected to it?

A useful sampling plan answers ten questions

A sampling plan does not need theatrical complexity. It needs enough detail that a trained person can collect the intended sample consistently and another qualified person can understand what the result represents.

1. What is the purpose?

The plan should state whether the sample is intended for:

incoming botanical identity;
alkaloid composition;
7-OH or mitragynine quantitation;
microbiological examination;
heavy-metal analysis;
pesticide or mycotoxin analysis;
moisture or water activity;
packaging and label examination;
a complaint investigation;
stability monitoring;
process verification; or
a legal-threshold decision.

One sample may support several compatible tests, but compatibility should be evaluated. The collection tools, container, amount, storage conditions, and laboratory preparation needed for microbial work may differ from those for chemical analysis.

2. What exactly is the lot?

Record the product, form, lot or batch number, source lot when applicable, total quantity, number and type of containers, manufacturing or receipt date, and physical location. If the material has already been divided among multiple rooms, pallets, drums, totes, or finished-package cases, the plan should account for that distribution.

3. Which containers or locations will be selected?

The selection should follow a pre-established rule rather than sampler convenience. A plan might use random container selection, stratified selection across pallets, or defined collection points across a process. The right design depends on lot structure and the hazard or characteristic being measured.

4. Where within each container will material be collected?

Surface scoops can overrepresent the top layer. For a dry powder, a plan may call for portions from different depths or zones when doing so is safe and scientifically appropriate. For capsules or retail packages, units may be selected across the beginning, middle, and end of a packaging run. Liquids may require defined mixing conditions before sampling.

5. How many primary increments or sample units are needed?

There is no responsible universal answer such as “one scoop per lot.” The number depends on lot size, expected uniformity, analyte distribution, product form, purpose, historical performance, method needs, and the consequences of a wrong decision.

FDA’s BAM Chapter 1 emphasizes that the number of units needed for a representative sample depends on statistical considerations and on the composition and uniformity of the lot. It also notes that sample units should be selected randomly for representativeness. FDA BAM Chapter 1

6. Will portions remain separate or become a composite?

Separate samples preserve information about variation among locations. A composite combines portions before analysis and produces a result for the combined material. Neither is universally better.

A composite may efficiently estimate an average chemical concentration when the method and decision rule support that design. But compositing can dilute a localized high result and hides which original location contributed it. For some pathogen methods, compositing may be specifically described by the method; for other purposes it may reduce the ability to find nonuniformity. The plan and laboratory must agree on the design before collection.

7. What tools and containers are appropriate?

The plan should identify clean or sterile sampling tools as required, compatible containers, closure type, labels, tamper evidence, and any blank or control containers. Tools should not introduce the analyte being measured. A metal tool or cap may be inappropriate for some elemental investigations; a nonsterile scoop may compromise microbial work; a permeable container may allow moisture change.

8. How will the sample be protected?

Protection may include light control, temperature control, moisture protection, prompt shipment, segregation from chemicals, and secure closure. FDA’s BAM instructs collectors to maintain original storage conditions as nearly as possible and to document collection and arrival dates and times. FDA BAM Chapter 1

9. How will identity and custody be documented?

The record should connect the physical sample to the lot without ambiguity. FDA’s current laboratory-package procedure says the collector should verify the lot’s location and identity; document the collection method, preparation, lot size and identification, sample size, collector identity, observations, and chain of custody; and preserve sample integrity during preparation and shipment. FDA laboratory procedure for private analytical packages

10. What decision will the result support?

The plan should identify the specification and decision rule in advance. A release test, screening test, investigation sample, and exploratory research sample serve different purposes. If the result lies close to a legal or internal limit, measurement uncertainty and sampling uncertainty both deserve attention.

Grab samples, increments, composites, and laboratory portions

Sampling language can become confusing because one object may be divided several times.

Grab sample

A grab sample is collected from one place at one time. It can be useful for investigating a specific location or observing process change. It should not automatically be presented as representative of an entire large lot.

Primary increment

An increment is an individual quantity taken from a selected point, container, or time. Multiple increments may remain separate or be combined according to the plan.

Composite sample

A composite sample combines defined increments. The result describes the mixture under the method’s assumptions. It may obscure variation among the increments.

Field sample or submitted sample

This is the material delivered to the laboratory. It may include multiple separately identified units or one composite.

Laboratory sample

The laboratory may reduce, mix, grind, divide, or otherwise prepare the submitted material according to its method. The smaller analytical portion placed into an instrument or culture medium is only one part of the received sample.

Reserve sample

A reserve sample is held for future examination, often for complaint, stability, or investigation work. It is not simply leftover powder in an unlabeled bag.

Keeping these terms straight helps answer a critical question: at what stage might important variation have been lost?

Why compositing requires judgment

Suppose ten increments contain different concentrations of a measured compound. If they are thoroughly combined and one portion of the composite is tested, the reported result may approximate the average concentration of that composite. It does not show whether one original increment was much higher or lower.

For example, nine increments at a low concentration and one high increment may produce a moderate composite result. That can be useful when the specification applies to the true lot average and the lot is intended to be uniform. It may be unhelpful when each retail unit must comply independently or when a localized contaminant matters.

Microbiological testing raises another concern: pathogens can be sparse and unevenly distributed. Increasing the amount or number of material units examined can improve the opportunity to encounter contamination, but no finite negative sample proves that every gram in a lot is free of a microorganism. The correct number of units and compositing scheme should come from the applicable validated method and sampling plan—not improvised arithmetic.

FDA’s BAM provides commodity- and method-specific instructions and describes cases where analytical units may be composited. Those instructions should not be copied mechanically onto kratom without assessing the product, hazard, and laboratory method. FDA Bacteriological Analytical Manual

Sampling kratom powder

Dry botanical powder can appear uniform while still containing meaningful variation.

Particle size differences can cause segregation during transport and vibration. Fine and coarse particles may move differently. Moisture can vary by location. A contaminant introduced before or after milling may not be evenly distributed. Blended source material can retain pockets if the process is inadequate. Material can also change between a bulk bag, a hopper, and finished packages.

A powder sampling plan should consider:

number of bulk containers and their arrangement;
whether containers came from one or multiple source lots;
whether the product was adequately blended before sampling;
collection from more than one location or depth when appropriate;
cross-contamination prevention;
cleaning status of the sampling tool;
whether microbial portions need aseptic technique;
protection from humidity during sampling;
the minimum material needed for every planned test, repeat, confirmation, and reserve; and
whether the submitted sample will be homogenized before analytical portions are removed.

“Sampled from a 25-kilogram bag” is incomplete. A useful record says which bag, where in the bag, how it was selected, how much was collected, what tool was used, whether portions were combined, and what happened next.

Sampling pure-leaf capsules

Kiody describes its botanical capsules as pure-leaf kratom, approximately 500 milligrams of powder per capsule. Sampling finished capsules involves at least two questions:

Does the powder inside the selected capsules represent the batch?
Do the finished units meet fill, packaging, and labeling expectations?

For chemical analysis, the laboratory may combine and homogenize the contents of several capsules. The COA should make clear whether the result is reported per gram of powder, per capsule, per serving, or in another unit. A powder concentration cannot be converted to a per-serving amount without the applicable serving mass.

For net-fill or capsule-weight checks, individual unit variation may matter. Averaging a group can hide unusually light or heavy capsules. For packaging review, selected bottles should cover the packaging run rather than all coming from one adjacent case.

Capsules also illustrate why source and finished-product tests are different. A source-powder COA may support supplier review, but it does not directly examine capsule filling, possible mix-ups, finished packaging, serving declarations, or changes after the powder was tested.

Sampling extracts and enhanced products

Extracts require product-specific plans because “extract” describes many matrices. A dry extract powder, viscous resin, tincture, aqueous liquid, and multilayer beverage do not behave the same way.

Questions include:

Does the product separate during storage?
Is mixing required before collection or use?
Can material adhere to the vessel wall or closure?
Does the product contain suspended solids?
Is the stated serving delivered by mass, volume, dropper, pump, tablet, or capsule?
Was the sample collected before or after final dilution?
Does the sampling container adsorb or react with relevant analytes?
Is the product stable during transport to the laboratory?

An extract result should not be borrowed to represent botanical leaf. Likewise, a raw extract result does not necessarily represent every finished formulation made from it. Finished-product sampling becomes especially important when the legal test is expressed per gram, per milliliter, per serving, per article, or as a percentage of total alkaloids.

Kiody does not sell concentrated 7-OH. This distinction matters because ordinary botanical leaf and products deliberately concentrated, enhanced, synthesized, or semi-synthesized for 7-OH exposure should not be grouped under one vague “kratom tested” label.

Sampling liquids

Liquids are sometimes assumed to be automatically uniform. That assumption should be verified.

Some liquids settle, stratify, crystallize, form gradients, or hold suspended material. A sample drawn from the top of an unmixed container may differ from the bottom. If a product’s directions require shaking, the sampling procedure should define whether and how the container or batch is mixed before collection. If mixing creates foam or changes volume readings, the procedure should address that too.

Bulk-tank samples may be collected from defined stages or points. Finished bottles may be selected across the filling run. A strong record identifies the tank or batch, mixing status, collection time relative to production, sample location, temperature when relevant, and the individual finished units selected.

For microbial work, opening a container creates contamination opportunities. Whenever possible, unopened finished units can reduce handling, but the appropriate approach depends on the testing purpose and method.

Different analytes create different sampling problems

Alkaloids and 7-OH

Alkaloid testing asks whether selected material contains a measured concentration or amount. The sampling plan must support the unit in which the result and specification are expressed.

For a percentage by dry weight, moisture basis and sample preparation may matter. For milligrams per gram, the tested matrix must be clear. For milligrams per serving, the serving mass or volume and calculation must be documented. For a percentage of total alkaloids, both the numerator and the total-alkaloid denominator must be defined and measured consistently.

Near a legal threshold, a single convenient scoop creates weak evidence. Lot variability, sample preparation, analytical uncertainty, rounding, and the jurisdiction’s exact formula should all be evaluated. A COA that reports only “7-OH: pass” without an actual result, unit, method, reporting limit, lot number, and sampling context is difficult to audit.

Heavy metals

Metals may enter botanicals through soil, water, processing, equipment, or contamination. Distribution can be uneven, particularly where foreign material or particulate contamination is involved. The sampling tool and container should not contribute the metal being measured. Sample digestion and instrumental analysis occur after collection; they cannot reveal areas of the lot that were never sampled.

Pathogens

Pathogens such as Salmonella may be present in small, irregular pockets. A negative result means the organism was not detected in the analyzed quantity under the stated method and conditions. It does not prove absence from every unit of the lot.

The COA should identify the method, sample amount or analytical unit when available, result language, and any reporting qualification. Sampling records should show how the laboratory portions connect to the lot.

Aerobic counts, yeast, and mold

Enumeration results describe the tested material and method. Counts can vary within a lot. Storage time, temperature, humidity, and sample handling can affect results. A sampling plan should preserve the condition being evaluated and avoid treating one count as a timeless characteristic of every package.

Pesticides and mycotoxins

These analytes may require specialized extraction and can be heterogeneously distributed. The target list matters: “pesticide tested” does not mean every possible pesticide was examined. “Mycotoxin tested” should identify which toxins were included.

Moisture and water activity

Exposure to room air during sampling can change a dry powder. Moisture content and water activity are related but different measurements. The plan should minimize uncontrolled exposure, identify the container and closure, and document whether the sample came from bulk material or a finished package.

Sampling error and analytical error are not the same

Every reported number contains uncertainty from more than one stage.

Sampling variation reflects differences among locations, units, times, or portions in the lot.

Sample-preparation variation can arise during grinding, mixing, subsampling, extraction, dilution, or digestion.

Analytical variation comes from the measurement process itself, including calibration, recovery, repeatability, and instrument performance.

Running duplicate injections from the same prepared solution mainly examines a narrow part of analytical repeatability. It does not show whether a different bag, pallet, bottle, or capsule would have produced the same result.

Similarly, splitting one jar between two laboratories is not the same as independently sampling the lot twice. The split can compare laboratory performance on similar material, but both laboratories inherit the original sampling choices.

When businesses investigate conflicting COAs, they should map the entire sequence:

lot → collection locations → increments → composite or separate units → submitted sample → laboratory preparation → analytical portions → reported result.

The disagreement may have begun long before either instrument was turned on.

Random, systematic, and stratified selection

These terms describe different ways of choosing units.

Random selection

Each eligible unit has a defined chance of selection. Randomization helps reduce conscious or unconscious preference for easy-to-reach, clean-looking, or recently produced units. A documented random-number process can be more defensible than “selected at random” written after the fact.

Systematic selection

Units are chosen at a defined interval—for example, at specified points across a filling run. The starting point and interval should be established without creating a pattern that accidentally aligns with process cycles.

Stratified selection

The lot is divided into meaningful groups, and units are selected from each group. Pallet, drum, production time, source lot, or packaging line could define a stratum. Stratification is useful when variation may follow the lot’s physical or production structure.

No design guarantees perfection. The design should match the question and be written before results are known.

Chain of custody is part of data quality

Chain of custody is the documented path showing who possessed or controlled the sample from collection through receipt and analysis.

A useful custody record can include:

unique sample identifier;
product and lot identifier;
date, time, and location of collection;
collector’s name or initials;
amount and number of units collected;
seal or tamper-evidence identifier;
requested analyses;
storage conditions;
each transfer, with date, time, sender, and receiver;
shipping condition and tracking reference;
laboratory receipt date and condition;
discrepancies, damage, leakage, temperature deviation, or broken seals; and
disposition of remaining material.

Custody documentation does not make a sample representative by itself. It protects the identity and integrity of the selected sample and allows reviewers to identify gaps.

Reserve samples are not retesting shortcuts

Reserve samples support later investigations. Under 21 CFR §111.83, the dietary-supplement CGMP framework requires a reserve sample from each distributed lot of packaged and labeled product, stored in the same or essentially equivalent container-closure system, identified by lot or control number, and held in at least twice the quantity needed for all specification tests. The rule provides retention periods tied to shelf-life dating or the date of last distribution. 21 CFR §111.83

Again, this is presented as a rigorous quality-system benchmark, not a statement that FDA accepts kratom as a lawful dietary supplement.

A reserve sample should be:

genuinely connected to the distributed lot;
packaged so its condition remains relevant;
protected under documented storage conditions;
large enough for the intended investigation;
access controlled;
periodically inventoried; and
accompanied by records showing any opening, removal, or testing.

If an original result fails, testing a reserve until one portion passes is not a scientifically honest resolution. A retest should follow a documented investigation, address the possible cause, and interpret all valid results. The reserve is evidence, not an eraser.

What a COA should disclose about sampling

Many COAs identify the lot and laboratory but say little about collection. A buyer or quality reviewer can ask for a sampling record or supporting statement covering:

who collected the sample—the manufacturer, supplier, independent sampler, or laboratory;
where the sample was collected;
collection date;
exact lot and lot size;
number of containers or finished units represented;
number and location of increments;
selection method;
whether increments were tested separately or composited;
total submitted quantity;
sample condition and container;
custody and shipping details;
laboratory receipt condition; and
preparation performed before analysis.

The phrase “third-party lab tested” describes who performed the analysis, not who selected the sample. A laboratory may test exactly what it receives without ever seeing the production lot. That can still be valuable, but the scope should be stated accurately.

Twelve sampling red flags

The COA lot number does not exactly match the package. Similar is not the same.
The lot is undefined. No batch quantity, container count, or source relationship is available.
One scoop was taken from the easiest location. Convenience replaced a selection plan.
All finished units came from one adjacent case. The packaging run is not represented.
The sample was sent by a supplier, but the record calls it independently sampled. Collection and analysis are different roles.
A composite result is used to claim every unit meets the limit. The composite may hide unit-to-unit variation.
The sample mass is too small for the requested work. Multiple analyses, repeats, confirmations, and reserves require enough material.
Microbial material was handled with nonsterile tools. The collection process may compromise the result.
A liquid was sampled without recording mixing status. Top and bottom may differ.
The result unit does not match the sampling or legal unit. Percent, mg/g, mg/mL, mg/serving, and percent of total alkaloids are not interchangeable.
An old source-material COA is used for a new finished batch. It does not examine the new manufacturing and packaging steps.
No reserve exists after a complaint. The investigation may have no unopened, lot-matched material to examine.

Four worked examples

Example 1: A botanical powder lot

A business receives 20 sealed bags identified as one supplier lot. The sampler opens the top of one bag and submits 30 grams for alkaloid, metals, and microbial work.

The laboratory may produce valid results for the submitted 30 grams. The weakness is the claim that those results represent all 20 bags. The collection record does not establish random or stratified bag selection, coverage across the lot, collection within bags, aseptic microbial technique, or enough material for all requested analyses and reserve work.

A stronger plan would define the lot, select bags using a documented rule, specify increments and tools by analyte, preserve separate microbial handling, and record any composite design.

Example 2: Pure-leaf capsules

A capsule run fills 10,000 bottles. Twenty bottles from the first case are tested for alkaloid concentration, and the business describes the entire run as verified.

Those bottles may not represent the middle and end of the run. A more defensible plan would select finished units across production time or packaging strata. If the concern includes capsule fill consistency, the procedure should examine individual-unit variation rather than only a pooled chemical average.

Example 3: A two-layer liquid

A liquid extract separates visibly during storage. A sample is drawn from the upper layer without mixing, and the result is reported per milliliter.

The number describes the sampled layer under those conditions. It may not represent the bottle after following the product’s mixing directions or the full bulk batch. The sampling procedure should define mixing, rest time, temperature, and collection location.

Example 4: A result near a 7-OH threshold

A composite powder result is close to a jurisdiction’s numerical 7-OH limit. The business rounds the value down and releases the lot.

That decision ignores at least four questions: whether the composite represents the lot, whether individual units may differ, what measurement uncertainty applies, and whether the jurisdiction evaluates dry weight, product weight, per-serving amount, per-article amount, or total-alkaloid composition. Near-limit decisions need an approved rule that accounts for both the legal formula and uncertainty. A favorable rounded display is not a compliance strategy.

A proposed 25-field Kiody sampling record

For review and adaptation by qualified quality and legal personnel, Kiody could use a sampling record containing:

sample record number;
purpose of sampling;
product name and form;
Kiody lot or control number;
supplier lot or lots;
manufacturing, packaging, or receipt date;
total lot quantity;
number and type of lot containers;
physical location and pallet or container map;
required analyses;
applicable specification and result unit;
selection design—random, systematic, stratified, or investigation-targeted;
selection method or randomization record;
containers or time points selected;
increment locations and depths when applicable;
number and size of increments;
separate-unit or composite design;
sampling tools and their preparation status;
sample containers and closures;
mixing or homogenization performed before collection;
collector identity, date, and time;
observations and deviations;
seal, storage, shipping, and custody record;
laboratory receipt condition and assigned laboratory ID; and
reserve-sample identity, quantity, storage location, and retention date.

The form should not replace a scientifically justified sampling procedure. Its purpose is to make that procedure auditable.

Current federal 7-OH status as of August 29, 2026

Sampling has become especially important because proposed and enacted federal actions use chemical identities and numerical thresholds that should not be blurred together.

The threshold proposal is not yet an effective scheduling order

On July 6, 2026, DEA published a notice of intent concerning 7-OH above a specified threshold. The proposal describes:

botanical Mitragyna speciosa material containing more than 0.050% 7-OH on a dry-weight basis; and
certain alternative, synthetic, extract, concentrate, edible, or pressed forms containing more than 0.050% by an applicable weight or volume measure, or more than 1.00 milligram of 7-OH in the article.

The HHS request for information concerns that proposed threshold. On August 26, 2026, HHS extended the public-comment deadline to September 10, 2026. A notice of intent and request for information are not the same as an effective final or temporary scheduling order. DEA notice of intent, HHS comment extension

For quality teams, the proposal illustrates why sampling documentation needs the product form, dry-weight basis when applicable, unit, article or serving definition, and lot structure. A lab number without that context may not answer the legal question.

DEA’s separate temporary order placed mitragynine pseudoindoxyl, MGM-15, and MGM-16 in Schedule I effective August 26, 2026, through August 26, 2028 unless extended or made permanent through further action. Unauthorized retail sale and possession are not permitted under the federal Controlled Substances Act. This order is effective now and does not depend on the pending 7-OH-threshold proposal. Federal temporary scheduling order

Kiody does not sell concentrated 7-OH, mitragynine pseudoindoxyl, MGM-15, or MGM-16.

Questions consumers can ask without pretending to be laboratory auditors

Consumers do not need to reconstruct a full statistical plan before buying a product. They can ask a few practical questions:

Does the lot number on the COA match the package?
Is the result for finished product or only raw material?
Who collected the sample?
Does the COA show actual results and units, not only “pass”?
Are methods identified?
Is the product form on the COA the same as the product being offered?
Is the COA recent enough to belong to the current lot?
Are botanical leaf and concentrated or synthetic products clearly separated?
Does the seller avoid unsupported medical claims?
Is there a way to report a product-quality concern with the lot number?

No single “yes” proves quality. Together, the answers can show whether a seller treats testing as traceable evidence or as a generic badge.

Frequently asked questions

Does one sample prove an entire kratom lot is safe?

No. A sample result provides evidence about the material tested under the sampling plan and method. It cannot prove that every gram or unit is free of every hazard.

What is the difference between a lot sample and a reserve sample?

A lot sample is collected for a current examination or test. A reserve sample is held for possible future investigation or testing. A portion may be collected during the same event, but its purpose, quantity, container, custody, and retention should be documented separately.

Is a composite sample better than separate samples?

Not automatically. A composite can efficiently describe combined material, but it hides variation among the original increments. Separate units preserve location-specific information but require more testing. The correct choice depends on the analyte and decision.

Can a laboratory make an unrepresentative sample representative?

No. A laboratory can homogenize the material it receives and use a suitable method. It cannot collect information from parts of the original lot that were never sampled.

Does “independently lab tested” mean independently sampled?

Not necessarily. An independent laboratory may analyze a sample chosen and mailed by the seller or supplier. The sampling record should identify who collected it.

Why do microbial and alkaloid tests need different sampling considerations?

An alkaloid may be distributed more broadly through a blended powder, while a pathogen can occur in sparse pockets. Collection tools, aseptic technique, sample quantity, compositing, and interpretation therefore may differ.

Can several tests use material from the same jar?

Sometimes, but the plan should ensure enough material, compatible containers and handling, and no compromise of microbial or other sensitive analyses. Laboratories should confirm requirements before collection.

Is the supplier’s COA enough?

It can be useful evidence, but its value depends on supplier qualification, lot match, sampling, methods, actual results, and the relationship between the source material and finished product. Under the Part 111 dietary-supplement framework, reliance on certain supplier COAs requires establishing and periodically reconfirming supplier reliability. 21 CFR §111.75

What if two laboratories report different results?

Review whether they tested the same lot, same physical sample, same matrix, same units, and comparable methods. Then examine sampling locations, preparation, calibration, uncertainty, and any deviations. Different results do not automatically prove that one laboratory is wrong.

Does a negative Salmonella result mean the whole lot contains no Salmonella?

No. It means Salmonella was not detected in the analyzed amount under the stated method and conditions. Sparse contamination can be missed by finite sampling.

Why does the serving definition matter for 7-OH?

Some restrictions use a per-serving or per-article limit, while others use concentration, dry weight, product weight, volume, or percentage of total alkaloids. The laboratory result and label serving must support the exact legal calculation.

Are botanical leaf and concentrated 7-OH the same sampling problem?

No. They differ in composition, manufacturing history, expected concentration, uniformity, product form, and legal treatment. Kiody does not sell concentrated 7-OH.

Should every kratom batch be tested?

Testing frequency should follow applicable law, risk, product and process knowledge, specifications, supplier performance, and a documented quality plan. No universal statement in this guide replaces jurisdiction-specific legal advice or qualified quality review.

What should happen if the sample seal is broken on arrival?

The laboratory should document the condition and follow its acceptance or rejection procedure. The client and quality unit should decide whether the sample remains suitable for the requested purpose. A compromised sample should not quietly proceed as though nothing happened.

Can a passing retest erase a failing result?

No. All valid results should be evaluated through an investigation. Retesting must have a documented scientific reason and should not become repeated testing until a pass appears.

The practical takeaway

A COA is not just an instrument printout. It is the end of a chain that begins with a defined lot and a defensible selection plan.

The strongest product-quality records connect:

a clearly defined lot;
a risk-appropriate sampling design;
clean or sterile collection practices as required;
traceable custody and storage;
a suitable, scientifically valid method;
actual results and units;
pre-established specifications and decision rules;
finished-product and serving context; and
a properly identified reserve sample.

The most honest claim is not “one COA proves everything.” It is that a documented sample was tested for named characteristics using stated methods, and the results are interpreted within their real limits.

That kind of transparency is less flashy than a testing badge. It is also far more useful.